A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukaemia (AML)
Leukemia
Blood Cancer
Blood Cancers

Interventions

DRUG: Tagraxofusp
DRUG: Azacitidine (AZA)
DRUG: Venetoclax

Sponsor

Jacqueline Garcia, MD

Collaborators

[object Object]
[object Object]